[Adults] Nuvilex, Inc.'s Cell Encapsulation Could Play a Role in Multimodality Therapy of Patients

[Investment Updates]

Nuvilex, Inc.'s Cell Encapsulation May Play a
Role in Multimodality Usage of
Can_cer Patients

N u v i l e x, Inc.'s (OTCQB: N
V L X) has a technology in their cell
encapsulation practice that will very
possibly play some
role in the future of oncology. How large
that part will be is
liable upon the technology
continuing to get
firm results when it's tested. One such area where the technology has had an
occasion to ascertain its
value is in a preclinical analysis that was
described in the very
esteemed scientific publication,
International Journal of Can-cer.

In that test Nuvilex's cell encapsulation was
used together with ifosfamide and radi.ation for the
treating of pancreatic tumors in rats. The
type of cells encapsulated for the study were equal
to those used in the organization's two
self-governing Level 2 clinical trials in
advanced, inoperable pancreatic can-cer patients. These cells are
used because of the very
raised activity of CYP2B1, the ifosfamide-activating
enzyme. Outcomes of the study
showed that cell encapsulation and
ifosfamide together with radi.ation gave the
promptest positive
response to treatment and the highest
percentage of respondants of any of the four treatment
parties in the study.

260 Madisen Ave, Eighth Fl., N.Y., NY 10016 USA

The use of research materials issued by
the auth.or is done at your own risk. You are encouraged to do your own
research before making any investment decision in regards to
the secu rity discussed herein. The author has not been rewarded by any
entity in connection with the disbursement of these
materials. You should presume that as of the date of this report
or letter, the author, possibly along with or through our owners,
affiliates, employees and/or consultants,
(communally referred to as the author) has a
position in all company shares (and/or options of the shares) covered
herein that is consistent with the position set forth in our report. In
connection with NVLX, the author has taken a long position. Following the
distribution of any report or letter, the author
intends to continue engaging in trnsactns in the secu rity covered
herein, and we may be long, short, and/or neutral at any time hereafter
regardless of our initial position and we preserve the right to procure or
trade all or part of our position at any time without notice. This practice
could end in our trading securities at any time before, during, and/or
after the disbursement of this report.

List removal
[http://support.PLAYADELCARMENVACATIONRENTALS.COM/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=832]

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.polarhome.com/pipermail/adults/attachments/20130703/40dafd6c/attachment.html>